March 26 (Reuters) – The U.S. Food and Drug Administration has approved Novo Nordisk’s insulin injection, Awiqli, to control blood sugar levels in adults living with type 2 diabetes, the company said on Thursday.
(Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich)
Comments